|
1
|
Chemotherapy of metastatic colorectal
cancer. Prescrire Int. 19:219–224. 2010.PubMed/NCBI
|
|
2
|
Tran NH, Cavalcante LL, Lubner SJ,
Mulkerin DL, LoConte NK, Clipson L, Matkowskyj KA and Deming DA:
Precision medicine in colorectal cancer: The molecular profile
alters treatment strategies. Ther Adv Med Oncol. 7:252–262. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Binefa G, Rodríguez-Moranta F, Teule A and
Medina-Hayas M: Colorectal cancer: From prevention to personalized
medicine. World J Gastroenterol. 20:6786–6808. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Feng QY, Wei Y, Chen JW, Chang WJ, Ye LC,
Zhu DX and Xu JM: Anti-EGFR and anti-VEGF agents: Important
targeted therapies of colorectal liver metastases. World J
Gastroenterol. 20:4263–4275. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Banjerdpongchai R, Chanwikruy Y,
Rattanapanone V and Sripanidkulchai B: Induction of apoptosis in
the human Leukemic U937 cell line by Kaempferia parviflora
Wall.ex.Baker extract and effects of paclitaxel and camptothecin.
Asian Pac J Cancer Prev. 10:1137–1140. 2009.PubMed/NCBI
|
|
6
|
Weaver BA: How Taxol/paclitaxel kills
cancer cells. Mol Biol Cell. 25:2677–2681. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu Y, Xie L, Chen G, Wang H and Zhang R:
Effects of oridonin on proliferation of HT29 human colon carcinoma
cell lines both in vitro and in vivo in mice. Pharmazie.
62:439–444. 2007.PubMed/NCBI
|
|
8
|
Liu YQ, Mu ZQ, You S, Tashiro S, Onodera S
and Ikejima T: Fas/FasL signaling allows extracelluar-signal
regulated kinase to regulate cytochrome c release in
oridonin-induced apoptotic U937 cells. Biol Pharm Bull.
29:1873–1879. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hsieh TC, Wijeratne EK, Liang JY,
Gunatilaka AL and Wu JM: Differential control of growth, cell cycle
progression, and expression of NF-kappaB in human breast cancer
cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin,
diterpenoids from the Chinese herb Rabdosia rubescens. Biochem
Biophys Res Commun. 337:224–231. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou GB, Kang H, Wang L, Gao L, Liu P, Xie
J, Zhang FX, Weng XQ, Shen ZX, Chen J, et al: Oridonin, a
diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion
protein and shows potent antitumor activity with low adverse
effects on t(8;21) leukemia in vitro and in vivo. Blood.
109:3441–3450. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hu HZ, Yang YB, Xu XD, Shen HW, Shu YM,
Ren Z, Li XM, Shen HM and Zeng HT: Oridonin induces apoptosis via
PI3K/Akt pathway in cervical carcinoma HeLa cell line. Acta
Pharmacol Sin. 28:1819–1826. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gao FH, Liu F, Wei W, Liu LB, Xu MH, Guo
ZY, Li W, Jiang B and Wu YL: Oridonin induces apoptosis and
senescence by increasing hydrogen peroxide and glutathione
depletion in colorectal cancer cells. Int J Mol Med. 29:649–655.
2012.PubMed/NCBI
|
|
13
|
Cheng Y, Qiu F, Ye YC, Tashiro S, Onodera
S and Ikejima T: Oridonin induces G2/M arrest and
apoptosis via activating ERK-p53 apoptotic pathway and inhibiting
PTK-Ras-Raf-JNK survival pathway in murine fibrosarcoma L929 cells.
Arch Biochem Biophys. 490:70–75. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bu HQ, Liu DL, Wei WT, Chen L, Huang H, Li
Y and Cui JH: Oridonin induces apoptosis in SW1990 pancreatic
cancer cells via p53- and caspase-dependent induction of p38 MAPK.
Oncol Rep. 31:975–982. 2014.
|
|
15
|
Luo J, Deng ZL, Luo X, Tang N, Song WX,
Chen J, Sharff KA, Luu HH, Haydon RC, Kinzler KW, et al: A protocol
for rapid generation of recombinant adenoviruses using the AdEasy
system. Nat Protoc. 2:1236–1247. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu K, Zhou M, Wu QX, Yuan SX, Wang DX, Jin
JL, Huang J, Yang JQ, Sun WJ, Wan LH, et al: The role of IGFBP-5 in
mediating the anti-proliferation effect of tetrandrine in human
colon cancer cells. Int J Oncol. 46:1205–1213. 2015.
|
|
17
|
He BC, Gao JL, Zhang BQ, Luo Q, Shi Q, Kim
SH, Huang E, Gao Y, Yang K, Wagner ER, et al: Tetrandrine inhibits
Wnt/β-catenin signaling and suppresses tumor growth of human
colorectal cancer. Mol Pharmacol. 79:211–219. 2011. View Article : Google Scholar :
|
|
18
|
Owona BA and Schluesener HJ: Molecular
insight in the multifunctional effects of oridonin. Drugs RD.
15:233–244. 2015. View Article : Google Scholar
|
|
19
|
Wang S, Zhong Z, Wan J, Tan W, Wu G, Chen
M and Wang Y: Oridonin induces apoptosis, inhibits migration and
invasion on highly-metastatic human breast cancer cells. Am J Chin
Med. 41:177–196. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu DL, Bu HQ, Jin HM, Zhao JF, Li Y and
Huang H: Enhancement of the effects of gemcitabine against
pancreatic cancer by oridonin via the mitochondrial
caspase-dependent signaling pathway. Mol Med Rep. 10:3027–3034.
2014.PubMed/NCBI
|
|
21
|
Liu Y, Liu JH, Chai K, Tashiro S, Onodera
S and Ikejima T: Inhibition of c-Met promoted apoptosis, autophagy
and loss of the mitochondrial transmembrane potential in
oridonin-induced A549 lung cancer cells. J Pharm Pharmacol.
65:1622–1642. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gao SY, Li J, Qu XY, Zhu N and Ji YB:
Downregulation of Cdk1 and cyclinB1 expression contributes to
oridonin-induced cell cycle arrest at G2/M phase and growth
inhibition in SGC-7901 gastric cancer cells. Asian Pac J Cancer
Prev. 15:6437–6441. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li X, Li X, Wang J, Ye Z and Li JC:
Oridonin up-regulates expression of P21 and induces autophagy and
apoptosis in human prostate cancer cells. Int J Biol Sci.
8:901–912. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gao FH, Hu XH, Li W, Liu H, Zhang YJ, Guo
ZY, Xu MH, Wang ST, Jiang B, Liu F, et al: Oridonin induces
apoptosis and senescence in colorectal cancer cells by increasing
histone hyperacetylation and regulation of p16, p21, p27 and c-myc.
BMC Cancer. 10:6102010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cui Q, Tashiro S, Onodera S, Minami M and
Ikejima T: Oridonin induced autophagy in human cervical carcinoma
HeLa cells through Ras, JNK, and P38 regulation. J Pharmacol Sci.
105:317–325. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Feng FF, Zhang DR, Tian KL, Lou HY, Qi XL,
Wang YC, Duan CX, Jia LJ, Wang FH, Liu Y, et al: Growth inhibition
and induction of apoptosis in MCF-7 breast cancer cells by oridonin
nanosuspension. Drug Deliv. 18:265–271. 2011. View Article : Google Scholar
|
|
27
|
Li D, Wu LJ, Tashiro S, Onodera S and
Ikejima T: Oridonin induces human epidermoid carcinoma A431 cell
apoptosis through tyrosine kinase and mitochondrial pathway. J
Asian Nat Prod Res. 10:77–87. 2008. View Article : Google Scholar
|
|
28
|
Huang HL, Weng HY, Wang LQ, Yu CH, Huang
QJ, Zhao PP, Wen JZ, Zhou H and Qu LH: Triggering Fbw7-mediated
proteasomal degradation of c-Myc by oridonin induces cell growth
inhibition and apoptosis. Mol Cancer Ther. 11:1155–1165. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fresno Vara JA, Casado E, de Castro J,
Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Osaki M, Oshimura M and Ito H: PI3K-Akt
pathway: Its functions and alterations in human cancer. Apoptosis.
9:667–676. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Polivka J Jr and Janku F: Molecular
targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol
Ther. 142:164–175. 2014. View Article : Google Scholar
|
|
32
|
Carnero A, Blanco-Aparicio C, Renner O,
Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer,
therapeutic implications. Curr Cancer Drug Targets. 8:187–198.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Milella M, Falcone I, Conciatori F, Cesta
Incani U, Del Curatolo A, Inzerilli N, Nuzzo CM, Vaccaro V, Vari S,
Cognetti F, et al: PTEN: Multiple functions in human malignant
tumors. Front Oncol. 5:242015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Waniczek D, Śnietura M, Młynarczyk-Liszka
J, Pigłowski W, Kopeć A, Lange D, Rudzki M and Arendt J: PTEN
expression profiles in colorectal adenocarcinoma and its
precancerous lesions. Pol J Pathol. 64:15–20. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hsu CP, Kao TY, Chang WL, Nieh S, Wang HL
and Chung YC: Clinical significance of tumor suppressor PTEN in
colorectal carcinoma. Eur J Surg Oncol. 37:140–147. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Song MS, Salmena L and Pandolfi PP: The
functions and regulation of the PTEN tumour suppressor. Nat Rev Mol
Cell Biol. 13:283–296. 2012.PubMed/NCBI
|
|
37
|
Tormos AM, Taléns-Visconti R, Nebreda AR
and Sastre J: p38 MAPK: A dual role in hepatocyte proliferation
through reactive oxygen species. Free Radic Res. 47:905–916. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cui Q, Tashiro S, Onodera S, Minami M and
Ikejima T: Autophagy preceded apoptosis in oridonin-treated human
breast cancer MCF-7 cells. Biol Pharm Bull. 30:859–864. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Huang J, Yuan SX, Wang DX, Wu QX, Wang X,
Pi CJ, Zou X, Chen L, Ying LJ, Wu K, et al: The role of COX-2 in
mediating the effect of PTEN on BMP9 induced osteogenic
differentiation in mouse embryonic fibroblasts. Biomaterials.
35:9649–9659. 2014. View Article : Google Scholar : PubMed/NCBI
|
